Table 2.
Availability of systematically collected biomarker data at baseline and/or follow-up in CONCORD-AD network cohorts
| Biomarker | AIBL | BioFINDER-1 | MCSAa,d | ||||||
| CU | MCI | AD | CUb | MCI | AD | CU | MCI | AD | |
| Measures of Aβ, n (%) | |||||||||
| PET | 145 (12)c | 36 (12)c | 19 (6)c | 272 (33) | 169 (58) | N/A | 1,592 (39)c | 156 (28)c | N/A |
| CSF Aβ42 | 27 (2) | 33 (11) | 140 (44) | 797 (96) | 288 (99) | 93 (100) | 719 (18)c | 64 (11) | N/A |
| Measures of Tau, n (%) | |||||||||
| PET | N/A | N/A | N/A | 52 | 42 | 2 | 579 (14)c | 35 (6) | N/A |
| CSF pTau | 27 (2) | 33 (11) | 140 (44) | 797 (96) | 288 (99) | 93 (90) | 719 (18)c | 64 (11) | N/A |
| CSF tTau | 27 (2) | 33 (11) | 140 (44) | 797 (96) | 288 (99) | 93 (100) | 719 (18)c | 64 (11) | N/A |
Aβ, amyloid-β; AD, Alzheimer’s disease; AIBL, Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing; AMI, AGRICA-MSA-Institut fédératif de recherche en santé publique/Aging Multidisciplinary Investigation; BioFINDER-1, Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably; CSF, cerebrospinal fluid; CU, cognitively unimpaired; MCI, mild cognitive impairment; MCSA, Mayo Clinic Study of Aging; N/A, not available; ND, non-demented; PET, positron emission tomography; pTau, phosphorylated tau; tTau, total tau; 3C Bordeaux, Three-City Study. aIn MCSA, PET and/or CSF biomarkers could be available at baseline and/or follow-up visits and not necessarily at the same study visit, as participants can select if they would like to undergo PET scans and/or lumbar puncture every time they visit the study. Follow-up visits occur every 15 months and neuroimaging studies are offered every 30 months or sooner if the participant’s cognitive status changes (e.g., progresses from CU to MCI). bBioFINDER-1 CU group also included individuals with SCD. cLongitudinal data available. dMCSA did not actively follow-up participants diagnosed with dementia at study baseline.